Congress Pushes To Turn Trump’s Psychedelic Therapy Order Into Law
A new bipartisan bill would take President Trump’s psychedelic therapy order and try to make it harder to undo. The measure, introduced by Reps. Morgan Luttrell, Lou Correa, Jack Bergman and Michael McCaul, would codify parts of the administration’s push to accelerate psychedelic research and access.
Its center of gravity is ibogaine, a powerful psychedelic compound that has drawn attention for trauma, addiction and veteran mental health. The bill does not make psychedelic therapy broadly legal. It tries to build a federal pathway around research, scheduling and access.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
An Overview
| Key takeaway | What it means |
|---|---|
| The bill would codify Trump’s order | Congress would turn parts of the executive action into law. |
| Ibogaine is the main focus | The bill targets research, scheduling review and access pathways. |
| Veterans remain central | Lawmakers framed the measure around PTSD, suicide risk and recovery. |
| Rescheduling could move faster | The attorney general would review ibogaine’s Schedule I status. |
| Access would still depend on evidence | The bill does not create open access or retail availability. |
Why This Bill Matters
Executive orders can change priorities. Laws are harder to reverse.
That is why this bill matters. Trump’s April order signaled federal support for faster psychedelic research and potential access. But a future administration could weaken, reinterpret or rescind that order.
Luttrell and his co sponsors are trying to lock in the direction of travel. Their bill would direct federal agencies to examine whether ibogaine and related compounds should move from Schedule I to Schedule II under the Controlled Substances Act.
That would not make ibogaine a standard treatment. But it could reduce barriers that slow research, manufacturing and clinical development.
Why Ibogaine Is At The Center
Ibogaine has become one of the most politically visible psychedelics in Washington. Veteran advocates have described it as life changing. Some researchers see potential for addiction, traumatic brain injury and severe psychiatric conditions.
It also carries real risks. Ibogaine can affect the heart, and unsafe use has been linked to serious adverse events. That is why the medical pathway matters.
The bill appears to embrace that tension. It does not simply call for wider availability. It points toward research, federal review, clinical evidence and controlled access.
In this field, that distinction is everything.
The Veteran Mental Health Argument
The political case for the bill rests heavily on veterans.
Lawmakers backing the measure describe PTSD, suicide risk and invisible wounds as urgent reasons to move faster. Luttrell, a former Navy SEAL, has also spoken publicly about his own experience with psychedelic therapy.
That personal connection gives the bill unusual emotional force. It also reflects a broader shift. Psychedelic medicine is no longer only a progressive reform issue. It now has bipartisan support from lawmakers who see it as a veteran care issue.
What Still Has To Happen
The bill would still need to move through Congress. Federal agencies would still need to act. Researchers would still need to generate enough data to satisfy regulators.
That means patients should not read this as immediate access.
A better reading is that Congress is trying to create pressure and structure. The goal is to keep psychedelic therapies from getting stuck between early promise and federal inertia.
The result could shape more than ibogaine. If Schedule I psychedelics complete late stage trials, the bill would push agencies to begin rescheduling proceedings.
That is the larger story. Psychedelic therapy is moving from advocacy into federal health policy. The question now is whether the law can move as carefully as the science requires, without moving so slowly that patients lose another decade.
